Brief: Cyclo Therapeutics Commences Patient Enrollment In Transportnpc, A Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ In Niemann-Pick Type C1
17/06/2021 13:10
June 17 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS COMMENCES PATIENT ENROLLMENT IN
TRANSPORTNPC,
A PIVOTAL PHASE 3 STUDY EVALUATING TRAPPSOL® CYCLO™ IN
NIEMANN-PICK TYPE C1
Source text for Eikon: ID:nBw92q5R7a
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug